Comparative study of the safety and efficacy of SMOFlipid vs non SMOFlipid as TPN for liver transplantation.
Fish oil
Liver transplantation
SMOFlipid
Journal
Annals of medicine and surgery (2012)
ISSN: 2049-0801
Titre abrégé: Ann Med Surg (Lond)
Pays: England
ID NLM: 101616869
Informations de publication
Date de publication:
Mar 2021
Mar 2021
Historique:
received:
17
12
2020
revised:
10
01
2021
accepted:
11
01
2021
entrez:
5
3
2021
pubmed:
6
3
2021
medline:
6
3
2021
Statut:
epublish
Résumé
Liver transplantation (LT) is one of the widely recognised and leading treatments for end-stage liver disease. Nutrition impacts its success. Total parenteral nutrition (TPN) is usually prescribed for patients recommended prolonged fasting after LT. The supplement of SMOFlipid (soybean oil, MCT oil, olive oil, and fish oil) is easily metabolised to produce energy, and it possesses anti-inflammatory effects; however, SMOFlipid emulsion use raises concerns regarding coagulopathy after LT. This study investigated the postoperative correlation between SMOFlipid and coagulation in LT. The medical records of 54 recipients of living donor LT between January 2012 and June 2015 were retrospectively reviewed. Patients with pretransplant platelet count <40,000/μL and >40,000/μL were assigned to the non-SMOFlipid (n = 23) group and the SMOFlipid (n = 31) group, respectively. The coagulation and nutrition profile of patients improved significantly after TPN support. No significant difference was observed in the coagulation profile between SMOFlipid and non-SMOFlipid groups. Although the SMOFlipid group exhibited a higher platelet count than the non-SMOFlipid group on day 7 (P < 0.001), no significant differences were observed in the platelet count on 14 and 30 days after TPN support between the 2 groups. TPN using SMOFlipid after LT is a good strategy for improving nutritional status without increasing the risks of bleeding and coagulation in patients intolerant of early enteral nutrition. Moreover, SMOFlipid use may not cause coagulopathy up to 14 days after LT. Overall, SMOFlipid provides nutritional benefits without increasing the risk of bleeding.
Sections du résumé
BACKGROUND
BACKGROUND
Liver transplantation (LT) is one of the widely recognised and leading treatments for end-stage liver disease. Nutrition impacts its success. Total parenteral nutrition (TPN) is usually prescribed for patients recommended prolonged fasting after LT. The supplement of SMOFlipid (soybean oil, MCT oil, olive oil, and fish oil) is easily metabolised to produce energy, and it possesses anti-inflammatory effects; however, SMOFlipid emulsion use raises concerns regarding coagulopathy after LT. This study investigated the postoperative correlation between SMOFlipid and coagulation in LT.
MATERIALS AND METHODS
METHODS
The medical records of 54 recipients of living donor LT between January 2012 and June 2015 were retrospectively reviewed. Patients with pretransplant platelet count <40,000/μL and >40,000/μL were assigned to the non-SMOFlipid (n = 23) group and the SMOFlipid (n = 31) group, respectively.
RESULTS
RESULTS
The coagulation and nutrition profile of patients improved significantly after TPN support. No significant difference was observed in the coagulation profile between SMOFlipid and non-SMOFlipid groups. Although the SMOFlipid group exhibited a higher platelet count than the non-SMOFlipid group on day 7 (P < 0.001), no significant differences were observed in the platelet count on 14 and 30 days after TPN support between the 2 groups.
CONCLUSION
CONCLUSIONS
TPN using SMOFlipid after LT is a good strategy for improving nutritional status without increasing the risks of bleeding and coagulation in patients intolerant of early enteral nutrition. Moreover, SMOFlipid use may not cause coagulopathy up to 14 days after LT. Overall, SMOFlipid provides nutritional benefits without increasing the risk of bleeding.
Identifiants
pubmed: 33664940
doi: 10.1016/j.amsu.2021.01.042
pii: S2049-0801(21)00025-X
pmc: PMC7905355
doi:
Types de publication
Journal Article
Langues
eng
Pagination
102094Informations de copyright
© 2021 Published by Elsevier Ltd on behalf of IJS Publishing Group Ltd.
Déclaration de conflit d'intérêts
All of authors in this study declared that there were no conflicts of interest.
Références
Am J Clin Nutr. 1997 May;65(5 Suppl):1687S-1698S
pubmed: 9129511
BMC Pediatr. 2014 Feb 18;14:48
pubmed: 24548745
Clin Nutr. 2009 Aug;28(4):387-400
pubmed: 19505748
Nat Clin Pract Gastroenterol Hepatol. 2006 Apr;3(4):202-9
pubmed: 16582962
Transplantation. 2001 Aug 27;72(4):666-70
pubmed: 11544428
Ann Surg. 2001 Apr;233(4):502-8
pubmed: 11303131
Liver Int. 2010 Feb;30(2):208-14
pubmed: 19840246
World J Gastroenterol. 2012 Nov 14;18(42):6141-7
pubmed: 23155344
Transplantation. 2000 Jan 27;69(2):258-64
pubmed: 10670636
Nutr Hosp. 2017 Feb 01;34(1):193-203
pubmed: 28244792
Br J Nutr. 2002 Jan;87 Suppl 1:S95-101
pubmed: 11895160
Crit Care. 2010;14(1):R5
pubmed: 20085628
Proc Nutr Soc. 2010 Nov;69(4):565-73
pubmed: 20441676
Clin Nutr. 2009 Aug;28(4):378-86
pubmed: 19464088
Crit Care Med. 2007 Mar;35(3):700-6
pubmed: 17261965
Nutrients. 2018 Dec 18;10(12):
pubmed: 30567387
Med Clin North Am. 2008 Jul;92(4):861-88, ix
pubmed: 18570946
Semin Liver Dis. 1985 Nov;5(4):349-56
pubmed: 3909429
Am J Clin Nutr. 2016 Feb;103(2):629S-34S
pubmed: 26791189
Proc Nutr Soc. 2006 Aug;65(3):264-77
pubmed: 16923311
Surg Clin North Am. 2011 Jun;91(3):565-78
pubmed: 21621696
JPEN J Parenter Enteral Nutr. 2010 Sep-Oct;34(5):503-12
pubmed: 20852178
J Clin Exp Hepatol. 2011 Dec;1(3):190-8
pubmed: 25755385
Int J Surg. 2019 Dec;72:156-165
pubmed: 31704426
Nutrition. 2010 May;26(5):474-81
pubmed: 20116213
Kidney Int. 2005 Mar;67(3):867-74
pubmed: 15698426
Crit Care. 2015 Apr 16;19:167
pubmed: 25879776
Postgrad Med. 2009 Nov;121(6):148-57
pubmed: 19940425
Curr Drug Targets. 2009 Aug;10(8):771-7
pubmed: 19702523
Ann Surg. 1993 Jan;217(1):82-91
pubmed: 8424706
Clin Nutr. 2013 Apr;32(2):224-31
pubmed: 22796064